This inventor holds 2 USPTO granted patents. Top assignees: King Abdulaziz University, University of Jeddah, Helwan University. Active years: 2025.
Company Filing History:
2 out of 588 
2 out of 12 
1 out of 1 Years Active: 2025
Title: Hind A Alkhatabi: Innovator in Cancer Treatment
Introduction
Hind A Alkhatabi is a prominent inventor based in Jeddah, Saudi Arabia. She has made significant contributions to the field of cancer research, particularly in the development of novel therapeutic agents for the treatment of acute myeloid leukemia and breast cancer. With two patents to her name, her work is paving the way for innovative solutions in oncology.
Latest Patents
Hind A Alkhatabi's latest patents include two significant inventions. The first patent is for 2-(5-aminopyridin-2-yl)-N-benzylacetamides and their use in the treatment of acute myeloid leukemia. This patent identifies three compounds that have a common molecular template, which are recognized as potential anticancer therapeutic agents. Compound I was specifically designed to target AML cells, inhibit their growth, and induce cell death. It demonstrated a dose-dependent effect on various AML cell lines, including HL-60, Mv4-11, KG-1a, and K562. The second patent involves aryl-1,2,3-triazole compounds, which have shown cytotoxic activities against MCF7 breast cancer cells. These compounds are useful in therapeutic regimes for breast cancer and have beneficial effects on critical pathways within MCF7 breast cancer cells.
Career Highlights
Hind A Alkhatabi has worked at notable institutions, including the University of Jeddah and King Abdulaziz University. Her academic and research endeavors have significantly contributed to the advancement of cancer treatment methodologies.
Collaborations
Hind has collaborated with several professionals in her field, including Roaa M Alreemi and Mohammed A Baradwan. These collaborations have enhanced her research and development efforts, leading to innovative solutions in cancer therapy.
Conclusion
Hind A Alkhatabi is a trailblazer in the field of cancer research, with her patents reflecting her commitment to developing effective treatments for acute myeloid leukemia and breast cancer. Her work continues to inspire advancements in oncology and offers hope for improved therapeutic options.